Total Payments
$561.65
2023 Payments
$67.60
Companies
6
Transactions
11
Medicare Patients
582
Medicare Billing
$55,461
Payment Breakdown by Category
Food & Beverage$512.93 (91.3%)
Education$48.72 (8.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $512.93 | 8 | 91.3% |
| Education | $48.72 | 3 | 8.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $296.37 | 4 | $0 (2020) |
| Melinta Therapeutics, Inc. | $68.39 | 1 | $0 (2018) |
| Nabriva Therapeutics, plc | $64.90 | 1 | $0 (2020) |
| Allergan Inc. | $64.39 | 1 | $0 (2019) |
| Insmed, Inc. | $48.72 | 3 | $0 (2023) |
| Apellis Pharmaceuticals, Inc. | $18.88 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $67.60 | 4 | Insmed, Inc. ($48.72) |
| 2020 | $143.64 | 2 | Merck Sharp & Dohme Corporation ($78.74) |
| 2019 | $208.15 | 3 | Merck Sharp & Dohme Corporation ($143.76) |
| 2018 | $68.39 | 1 | Melinta Therapeutics, Inc. ($68.39) |
| 2017 | $73.87 | 1 | Merck Sharp & Dohme Corporation ($73.87) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/01/2023 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 02/22/2023 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 01/07/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $18.88 | General |
| Category: Hematology | ||||||
| 01/05/2023 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 03/11/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $78.74 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Nabriva Therapeutics, plc | Xenleta (Drug) | Food and Beverage | In-kind items and services | $64.90 | General |
| Category: Antibiotic | ||||||
| 11/13/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $64.39 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/15/2019 | Merck Sharp & Dohme Corporation | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $65.58 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/20/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $78.18 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/16/2018 | Melinta Therapeutics, Inc. | Vabomere (Drug) | Food and Beverage | Cash or cash equivalent | $68.39 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 05/17/2017 | Merck Sharp & Dohme Corporation | DIFICID (Drug) | Food and Beverage | In-kind items and services | $73.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 163 | 275 | $54,358 | $15,647 |
| 2022 | 5 | 137 | 247 | $49,346 | $14,107 |
| 2021 | 6 | 136 | 210 | $40,837 | $12,548 |
| 2020 | 6 | 146 | 266 | $42,087 | $13,159 |
Total Patients
582
Total Services
998
Medicare Billing
$55,461
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 42 | 80 | $16,398 | $4,843 | 29.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 32 | 37 | $14,319 | $3,680 | 25.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 40 | 79 | $8,848 | $2,994 | 33.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $7,436 | $1,726 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 22 | 34 | $5,149 | $1,602 | 31.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 14 | 32 | $2,208 | $801.30 | 36.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 39 | 88 | $17,072 | $4,863 | 28.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 28 | 31 | $11,408 | $3,182 | 27.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 42 | 93 | $9,946 | $2,818 | 28.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 15 | $8,160 | $2,292 | 28.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 20 | $2,760 | $950.87 | 34.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 31 | 55 | $10,175 | $3,134 | 30.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 27 | 27 | $9,450 | $2,909 | 30.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $8,806 | $2,699 | 30.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 35 | 73 | $7,373 | $2,201 | 29.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 13 | $3,458 | $1,058 | 30.6% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 15 | 25 | $1,575 | $546.63 | 34.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 50 | 123 | $12,423 | $3,842 | 30.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 25 | 53 | $9,805 | $3,062 | 31.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 19 | 21 | $7,350 | $2,309 | 31.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 20 | 23 | $5,957 | $1,868 | 31.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 18 | $4,788 | $1,501 | 31.3% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 16 | 28 | $1,764 | $577.53 | 32.7% |
About Dr. David Liebers, M.D
Dr. David Liebers, M.D is a Infectious Disease healthcare provider based in Schenectady, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1245234905.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Liebers, M.D has received a total of $561.65 in payments from pharmaceutical and medical device companies, with $67.60 received in 2023. These payments were reported across 11 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($512.93).
As a Medicare-enrolled provider, Liebers has provided services to 582 Medicare beneficiaries, totaling 998 services with total Medicare billing of $55,461. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine
- Location Schenectady, NY
- Active Since 06/10/2005
- Last Updated 09/11/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1245234905
Products in Payments
- ZERBAXA (Drug) $156.92
- DIFICID (Drug) $73.87
- Vabomere (Drug) $68.39
- DELSTRIGO (Drug) $65.58
- Xenleta (Drug) $64.90
- AVYCAZ (Drug) $64.39
- Arikayce (Drug) $48.72
- Empaveli (Drug) $18.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.